» Articles » PMID: 9823964

Variable Presence of Hypoxia in M006 Human Glioma Spheroids and in Spheroids and Xenografts of Clonally Derived Sublines

Overview
Journal Br J Cancer
Specialty Oncology
Date 1998 Nov 21
PMID 9823964
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Recently we reported the variable presence of hypoxia adjacent to necrosis in human glioma lines grown as subcutaneous tumours in severe combined immunodeficient (SCID) mice. To assess the basis for this observation, we examined the pattern of oxygenation in M006 and M006XLo glioma spheroids. We found a wide range of binding of [3H]misonidazole to cells adjacent to the necrotic core, analogous to the patterns seen in xenografts, indicating substantial differences in the central oxygen tension of the spheroids. Clonal selection was used to isolate single cell-derived sublines of the M006XLo line. Some sublines gave spheroids that showed narrow distributions of [3H]misonidazole binding to the cells adjacent to necrosis, whereas other sublines showed a range of binding similar to that seen in spheroids of the parent line. After additional passages in monolayer culture, clonal sublines occasionally gave rise to spheroids in which the mean oxygen tension of cells adjacent to necrosis differed substantially from that of the initial spheroids. No relationship was evident between the thickness of the rim of viable cells and the presence or absence of central hypoxia, over a wide range of rim thickness. These results indicate that different oxygenation characteristics of glioma spheroids and tumour microregions are unlikely to arise from stable genetic variants coexisting in the parent line.

Citing Articles

Expression of Myoglobin in Normal and Cancer Brain Tissues: Correlation With Hypoxia Markers.

Elsherbiny M, Shaaban M, El-Tohamy R, Elkholi I, Hammam O, Magdy M Front Oncol. 2021; 11:590771.

PMID: 33996536 PMC: 8120281. DOI: 10.3389/fonc.2021.590771.


Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma.

Liu S, Tetzlaff M, Wang T, Chen X, Yang R, Kumar S Oncotarget. 2018; 8(70):115140-115152.

PMID: 29383148 PMC: 5777760. DOI: 10.18632/oncotarget.22944.


Metabolic remodeling precedes mitochondrial outer membrane permeabilization in human glioma xenograft cells.

Ponnala S, Chetty C, Veeravalli K, Dinh D, Klopfenstein J, Rao J Int J Oncol. 2011; 40(2):509-18.

PMID: 22076676 PMC: 3232313. DOI: 10.3892/ijo.2011.1255.


Targeting metabolic remodeling in glioblastoma multiforme.

Wolf A, Agnihotri S, Guha A Oncotarget. 2011; 1(7):552-62.

PMID: 21317451 PMC: 3035636. DOI: 10.18632/oncotarget.190.


Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas.

Chou S, Azuma Y, Varia M, Raleigh J Br J Cancer. 2004; 90(3):728-35.

PMID: 14760391 PMC: 2409601. DOI: 10.1038/sj.bjc.6601585.


References
1.
Hochachka P, Buck L, Doll C, Land S . Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci U S A. 1996; 93(18):9493-8. PMC: 38456. DOI: 10.1073/pnas.93.18.9493. View

2.
Rampling R, Cruickshank G, Lewis A, Fitzsimmons S, Workman P . Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys. 1994; 29(3):427-31. DOI: 10.1016/0360-3016(94)90432-4. View

3.
Parliament M, Franko A, Mielke B, Santos C, Wolokoff B, Mercer J . Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption. Br J Cancer. 1997; 75(3):311-8. PMC: 2063364. DOI: 10.1038/bjc.1997.52. View

4.
Kunz-Schughart L, Habbersett R, Freyer J . Mitochondrial function in oncogene-transfected rat fibroblasts isolated from multicellular spheroids. Am J Physiol. 1997; 273(5):C1487-95. DOI: 10.1152/ajpcell.1997.273.5.C1487. View

5.
Freyer J . Decreased mitochondrial function in quiescent cells isolated from multicellular tumor spheroids. J Cell Physiol. 1998; 176(1):138-49. DOI: 10.1002/(SICI)1097-4652(199807)176:1<138::AID-JCP16>3.0.CO;2-3. View